Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

Abbreviated New Drug Application (ANDA): 077654
Company: GLENMARK PHARMS LTD

• Other Important Information from FDA

Products on ANDA 077654

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
CITALOPRAM HYDROBROMIDE	CITALOPRAM HYDROBROMIDE	EQ 10MG BASE	TABLET;ORAL	Discontinued	None	No	No
CITALOPRAM HYDROBROMIDE	CITALOPRAM HYDROBROMIDE	EQ 20MG BASE	TABLET;ORAL	Discontinued	None	No	No
CITALOPRAM HYDROBROMIDE	CITALOPRAM HYDROBROMIDE	EQ 40MG BASE	TABLET;ORAL	Discontinued	None	No	No

Approval Date(s) and History, Letters, Labels, Reviews for ANDA 077654

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
02/27/2009	ORIG-1	Approval				Label is not available on this site.

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
10/07/2024	SUPPL-5	Labeling-Package Insert		Label is not available on this site.
11/20/2023	SUPPL-4	Labeling-Package Insert		Label is not available on this site.
09/16/2022	SUPPL-3	Labeling-Package Insert		Label is not available on this site.
09/16/2022	SUPPL-2	Labeling-Patient Package Insert		Label is not available on this site.
09/16/2022	SUPPL-1	Labeling-Package Insert		Label is not available on this site.